Hui Wei

Dr. Hui Wei


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2024 in Leukemia
Verified
Journal Article
Closed access
PDF file
DDDagrun Daltveit
Dagrun Daltveit
EMEileen Morgan
Eileen Morgan
MCMurielle Colombet
Murielle Colombet
ESEva Steliarova-Foucher
Eva Steliarova-Foucher
KBKarima Bendahhou
Karima Bendahhou
ISIsabelle Soerjomataram
Isabelle Soerjomataram

10 February 2018 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
HWHui Wei
Hui Wei
YWYing Wang
Ying Wang
CZChunlin Zhou
Chunlin Zhou
DLDong Lin
Dong Lin
BLBingcheng Liu
Bingcheng Liu
JWJIANXIANG WANG
JIANXIANG WANG
Racial and ethnic disparities in malignancies attract extensive attention. To investigate whether there are racial and ethnic disparities in genetic alteration between Caucasian and Eastern Asian population, data from several prospective AML trials were retrospectively analyzed in this study. We found that there were more patients with core binding factor (CBF) leukemia in Eastern Asian cohorts and there were different CBF leukemia constitutions between them. The ratios of CBF leukemia are 27.7, 22.1, 21.1, and 23.4%, respectively, in our (ChiCTR-TRC-10001202), another Chinese, Korean, and Japanese Eastern Asian cohorts, which are significantly higher than those in ECOG1900, MRC AML15, UK NCRI AML17, HOVON/SAKK AML-42, and German AML2003 (15.5, 12.5, 9.3, 10.2, and 12%, respectively). And CBFbeta-MYH11 occurred more prevalently in HOVON/SAKK AML- 42 and ECOG1900 trials (50.0 and 54.3% of CBF leukemia, respectively) than in Chinese and Japanese trials (20.1 and 20.8%, respectively). The proportion of FLT3-ITD mutation is 11.2% in our cohort, which is lower than that in MRC AML15 and UK NCRI AML17 (24.6 and 17.9%, respectively). Even after excluding the age bias, there are still different incidence rates of mutation between Caucasian and Eastern Asian population. These data suggest that there are racial and ethnic disparities in genetic alteration between Caucasian and Eastern Asian population.

8 November 2018 in Biomarker Research
Verified
Journal Article
Open access
PDF file
RGRunxia Gu
Runxia Gu
XYXue Yang
Xue Yang
HWHui Wei
Hui Wei
For decades, genetic aberrations including chromosome and molecular abnormalities are important diagnostic and prognostic factors in acute myeloid leukemia (AML). ATRA and imatinib have been successfully used in AML and chronic myelogenous leukemia, which proved that targeted therapy by identifying molecular lesions could improve leukemia outcomes. Recent advances in next generation sequencing have revealed molecular landscape of AML, presenting us with many molecular abnormalities. The individual prognostic information derived from a specific mutation could be modified by other molecular lesions. Therefore, the genomic complexity in AML poses a huge challenge to successful translation into more accurate risk stratification and targeted therapy. Herein, a summary of these mutations and targeted therapies are described. We focus on the prognostic information of recent identified molecular lesions and emerging targeted therapy.

18 March 2025 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
CSChenguang Sun
Chenguang Sun
XXXi Xu
Xi Xu
ZCZhongyang Chen
Zhongyang Chen
FZFanqi Zhou
Fanqi Zhou
WWWen Wang
Wen Wang
YMYanni Ma
Yanni Ma

25 January 2022 in Blood Science
Verified
Journal Article
Open access
XGXiaoyuan Gong
Xiaoyuan Gong
CLChunhong Li
Chunhong Li
YWYing Wang
Ying Wang
QRQing Rao
Qing Rao
YMYingchang Mi
Yingchang Mi
JWJIANXIANG WANG
JIANXIANG WANG
Introduction: Mature plasmacytoid dendritic cells (pDCs) proliferation associated with myeloid neoplasms (MPDMN) are recognized as a neoplasm related to fully differentiated pDCs. Although it has been reported for many years, the genomic landscape of MPDMN is poorly understood. Methods: We reported two patients who developed acute myeloid leukemia (French-American-British M5 subtype) coexisted with immunophenotypically mature pDCs proliferation, which fit the diagnosis of MPDMN. We sorted pDCs from myeloid blasts by flow cytometry and performed whole-exome sequencing and RNA sequencing of the two cell populations, respectively. Results: The immunophenotypes of pDCs in both patients were positive for CD123bri, HLA-DR, CD4, CD303, CD304, and negative for CD56, CD34, CD117, and TdT. The variant allele frequency of gene mutations in myeloid blasts and pDCs were similar. The expression data showed myeloid blasts clustered tightly with hematopoietic stem cells, and pDCs from patients clustered tightly with granulocyte-monocyte progenitors/common myeloid progenitor, rather than with pDCs from the GEO platform. Conclusion: Our study suggested that pDCs derived from the leukemic clone, evidenced by a shared mutation profile and similar transcriptional signatures between pDCs and concurrent myeloid blasts.

31 October 2024 in Leukemia
Verified
Journal Article
Closed access
PDF file
SQShaowei Qiu
Shaowei Qiu
YMYihan Mei
Yihan Mei
RGRunxia Gu
Runxia Gu
YLYu Liu
Yu Liu
MCManling Chen
Manling Chen
JWJIANXIANG WANG
JIANXIANG WANG